Eesti - eesti - Ravimiamet

meda pharma sia - flutikasoon+aselastiin - ninasprei, suspensioon - 50mcg+137mcg 1annus 120annus 3tk; 50mcg+137mcg 1annus 28annus 10tk

Eesti - eesti - Ravimiamet

orion corporation orion pharma - tsefaleksiin - õhukese polümeerikattega tablett - 250mg 14tk; 250mg 140tk; 250mg 20tk

Eesti - eesti - Ravimiamet

ge healthcare buchler gmbh & co. kg - naatriumjodiid (131i) - kõvakapsel - 5tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

paion deutschland gmbh - remimazolam besilate - teadlik sedatsioon - psühhoeptikumid - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

Eesti - eesti - Ravimiamet

ideal trade links uab - flutikasoon+aselastiin - ninasprei, suspensioon - 50mcg+137mcg 1mõõtannus 120mõõtannus 1tk

Eesti - eesti - Ravimiamet

lex ano uab - flutikasoon+aselastiin - ninasprei, suspensioon - 50mcg+137mcg 1mõõtannus 120mõõtannus 1tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - flutikasoon+aselastiin - ninasprei, suspensioon - 50mcg+137mcg 1mõõtannus 120mõõtannus 3tk

Eesti - eesti - Ravimiamet

teva b.v. - flutikasoon+aselastiin - ninasprei, suspensioon - 50mcg+137mcg 1mõõtannus 120mõõtannus 1tk

Eesti - eesti - Ravimiamet

teva b.v. - flutikasoon+aselastiin - ninasprei, suspensioon - 50mcg+137mcg 1mõõtannus 120mõõtannus 3tk; 50mcg+137mcg 1mõõtannus 120mõõtannus 1tk